Randomized Placebo-controlled Trial Of An Isoflavone Supplement And Menopausal Symptoms In Women

Effect None
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 43
Gender Female
Age Range 45-64
Body Types Overweight
Notes for this study:
Supplementation of 40mg Promensil daily over the course of three months was noted to reduce hot flashes relative to placebo when measured at four weeks, but over the course of the 12 week study there were no significant differences in overall menopausal symptoms (Greene Climacteric Scale) or hot flash occurrence.
Funding issues for this study:
Study was Financially Supported by producers of the supplement; Novagen

Effects Of A Red Clover Extract (MF11RCE) On Endometrium And Sex Hormones In Postmenopausal Women

Effect None
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 109
Gender Female
Age Range 45-64
Body Types Average
Notes for this study:
In postmenopausal women given the isoflavone supplement (MF11RCE) at 40mg twice daily for a period of 90 days, supplementation failed to influence estrogen or SHBG but appeared to increase testosterone concentrations in serum (22%) and decreased endometrial thickness.

The Effect Of Promensil, An Isoflavone Extract, On Menopausal Symptoms

Effect None
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 37
Gender Female
Age Range 45-64
Body Types Overweight
Notes for this study:
Supplementation of 40mg Promensil, but not 160mg, was able to increase HDL-C in postmenopausal women by 18% after twelve weeks, but no other biochemical marker nor menopausal symptom appeared to be influenced.
Funding issues for this study:
Funded by Novagen, producers of Promensil

Red-clover-derived Isoflavones And Mammographic Breast Density: A Double-blind, Randomized, Placebo-controlled Trial ISRCTN42940165

Effect None
Trial Design Double blind
Trial Length 6+ Months
Number of Subjects 177
Gender Both Genders
Age Range 45-64
Body Types Overweight, Average
Notes for this study:
One year of supplementation of 40mg Promensil was unable to exert appreciable estrogenic or antiestrogenic properties in the breast tissue of menopausal women without breast cancer as assessed by mammography; that being said, women with an ESR1 (estrogen receptor) genotype had minor antiestrogenic properties despite no differences in baseline levels.
Funding issues for this study:
Funded by Novagen, producers of Promensil

Red Clover Isoflavones Are Safe And Well Tolerated In Women With A Family History Of Breast Cancer

Effect None
Trial Design Double blind
Trial Length 6+ Months
Number of Subjects 401
Gender Female
Age Range 45-64
Body Types Average
Notes for this study:
Supplementation of red clover extract daily over the course of three years was safe and well tolerated in premenopausal and postmenopausal women, but was unable to influence breast density in women with a family history of breast cancer and did not influence serum lipid biomarkers or bone mineral density, although some alterations in bone mineral biomarkers were noted when controlling for menopausal women only.

The Effect Of Red Clover Isoflavones On Menopausal Symptoms, Lipids And Vaginal Cytology In Menopausal Women: A Randomized, Double-blind, Placebo-controlled Study

Effect None
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 53
Gender Female
Age Range 45-64, 65+
Body Types Overweight, Average
Notes for this study:
Supplementation of 80mg of red clover isoflavones daily to postmenopausal women for 90 days was able to reduce symptoms of menopause with minimal effects on the cardiovascular system nor the hormonal system.